首頁 > 市場調查報告書 > 製藥

抗血小板藥物市場：按藥物類別、給藥方法、應用、地區 - 規模、份額、前景、機會分析，2022-2030

市場調查報告書

商品編碼

1110234

抗血小板藥物市場：按藥物類別、給藥方法、應用、地區 - 規模、份額、前景、機會分析，2022-2030

Antiplatelet Drugs Market, by Drug Class, by Mode of Administration, by Application, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年07月28日 | 出版商:

Coherent Market Insights | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

為心髒病發作的人開具抗血小板藥物，這些藥物有助於防止心髒病發作再次發生。抗血小板藥物包括阿司匹林、氯□格雷、普拉格雷和替格瑞洛。除非存在超敏反應，否則建議所有急性冠狀動脈綜合徵 (ACS) 患者使用阿司匹林。它與口服抗血小板藥物如氯□格雷、普拉格雷和替格瑞洛一起開處方。普拉格雷被開給患有 ACS 或接受經皮冠狀動脈介入治療 (PCI) 的患者。氯□格雷和替格瑞洛有助於預防成人 ACS 患者和接受冠狀動脈旁路移植術 (CABG) 或 PCI 治療的患者的動脈粥樣硬化血栓事件。

市場動態

肥胖、糖尿病和心血管疾病 (CVD) 等慢性病不斷增加，增加了心髒病發作的風險，從而推動了對抗血小板藥物的需求。例如，根據美國糖尿病協會的數據，2019 年，3730 萬美國公民，或 11.3% 的人口患有糖尿病。在 3730 萬成年人中，約有 190 萬美國公民患有 1 型糖尿病，其中包括約 244,000 名兒童和青少年。在 3730 萬成年人中，有 2870 萬人被診斷患有糖尿病，850 萬人未確診。 2019 年，9600 萬 18 歲及以上的美國公民處於糖尿病前期。每年有 140 萬美國人被診斷出患有糖尿病。美國疾病控制與預防中心報告稱，2017-2018 年，心髒病每年給美國造成的損失約為 2290 億美元。這包括醫療服務、藥品和因死亡而導致的生產力損失等費用。根據疾病控制和預防中心的數據，2019 年美國約有 2010 萬 20 歲及以上的成年人患有冠狀動脈疾病。

本研究的主要特點

本報告對全球抗血小板藥物市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2030 年）的市場規模和復合年增長率 (CAGR%) 的增長。
解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
該研究還提供了有關市場驅動因素、抑制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
基於公司亮點、產品組合、關鍵亮點、財務業績和戰略等參數的全球抗血小板藥物市場主要參與者的概況。
本研究涵蓋的主要公司包括 AstraZeneca Plc、Boehringer Ingelheim GmbH、Bristol-Myers Squibb Company、Daiichi Sankyo, Inc.、Eli Lilly and Company、Merck & Co., Inc.、Otsuka Pharmaceutical Company, Ltd.。、賽諾菲和醫藥公司
本報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
《全球抗血小板藥物市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。
通過用於分析全球抗血小板藥物市場的各種戰略矩陣促進決策制定。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第2章市場展望

舉報內容
- 市場定義和範圍
執行摘要
- 市場快照：按藥物類別
- 市場快照：按劑型
- 市場快照：按應用
- 市場概況：按地區劃分
連貫的機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

市場動態
- 驅動程序
- 約束因素
- 市場機會
影響分析
市場趨勢
近期趨勢
收購和合作方案
技術概述
監管場景
定價分析
流行病學分析
波特五力

第 4 章全球抗血小板藥物市場 - 冠狀病毒 (COVID-19) 大流行的影響

整體影響
政府舉措
COVID-19 對市場的影響

第 5 章全球抗血小板藥物市場，按藥物類別，2017-2030 年

不可逆的環氧合□ (COX) 抑製劑
二磷酸腺甘 (ADP) 受體抑製劑
糖蛋白 IIB/IIIA 抑製劑
腺甘再攝取抑製劑
血栓素抑製劑和磷酸二酯□抑製劑

第 6 章全球抗血小板藥物市場，按劑型，2017-2030 年

口服給藥
靜脈給藥

第 7 章全球抗血小板市場：按應用，2017-2030 年

血管成形術
動脈血栓栓塞
心肌梗塞
經皮冠狀動脈介入治療
其他

第 8 章全球抗血小板藥物市場，按地區，2017-2030 年

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
英國
德國
意大利
法國
西班牙
俄羅斯
其他歐洲
亞太地區
中國
印度
日本
東盟
澳大利亞
韓國
其他亞太地區
中東
海合會
以色列
其他中東地區
非洲
北非
中非
南非

第 9 章競爭格局

熱圖分析
公司簡介
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo, Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Otsuka Pharmaceutical Company, Ltd.
- Sanofi
- The Medicines Company

第10章章節

參考文獻
調查手法

簡介目錄

Product Code: CMI2190

Antiplatelet drugs are prescribed to individuals with a history of heart attacks and these drugs aid in reducing reoccurrence of heart attacks. Some of the antiplatelet medications include, aspirin, clopidogrel, prasugrel, and ticagrelor. Aspirin is recommended for all patients with Acute Coronary Syndrome (ACS), in the absence of hypersensitivity. It is prescribed along with one of the oral antiplatelet agents including Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel is prescribed for patients suffering from ACS and for those undergoing Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor aid in preventing atherothrombotic events in adult patients with ACS, and those who are treated with Coronary Artery Bypass Grafting (CABG) or PCI.

Market Dynamics

Increasing incidence of chronic diseases such as obesity, diabetes, and cardiovascular diseases (CVDs) is increasing the risk of heart attacks, which in turn is propelling demand for antiplatelet drugs. For instance, according to American Diabetes Association, in 2019, 37.3 million U.S. citizens or 11.3% of the population, had diabetes. Of the 37.3 million adults, nearly 1.9 million U.S. citizens had type 1 diabetes, including about 244,000 children and adolescents. Of the 37.3 million adults with diabetes, 28.7 million were diagnosed, and 8.5 million were undiagnosed. In 2019, 96 million U.S. citizens age 18 and older had prediabetes. 1.4 million U.S. citizens are diagnosed with diabetes every year. According to report by Centers for Disease Control and Prevention, heart disease cost the U.S. about US$229 billion each year from 2017 to 2018. This included the cost of health care services, medicines, and lost productivity due to death. In the U.S. according to the Center for disease control, about 20.1 million adults age 20 and older had Coronary Artery Disease in the year 2019.

Key features of the study:

This report provides an in-depth analysis of the global antiplatelet drugs market , and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antiplatelet drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antiplatelet drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antiplatelet drugs market

Detailed Segmentation:

Global Antiplatelet Drugs Market , By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
Global Antiplatelet Drugs Market , By Mode of Administration:
- Oral
- Intravenous
Global Antiplatelet Drugs Market , By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
Global Antiplatelet Drugs Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- AstraZeneca Plc*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo, Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Otsuka Pharmaceutical Company, Ltd.
- Sanofi
- The Medicines Company

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Mode of Administration
- Market Snapshot, By Application
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pricing Analysis
Epidemiology Analysis
PORTER'S Five Forces

4. Global Antiplatelet Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Antiplatelet Drugs Market, By Drug Class, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Irreversible Cyclooxygenase (COX) Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Adenosine Diphosphate (ADP) Receptor Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Glycoprotein IIB/IIIA Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Adenosine Reuptake Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Antiplatelet Drugs Market, By Mode of Administration, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Intravenous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Antiplatelet Drugs Market, By Application, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Angioplasty
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Arterial Thrombosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Myocardial Infarction
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Percutaneous Coronary Interventions
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Antiplatelet Drugs Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa